Effects of spironolactone and RU486 on gene expression and cell proliferation after freshwater transfer in the euryhaline killifish.
We have explored the possible mechanisms by which mineralocorticoid (MR) and glucocorticoid (GR) receptors regulate the response to freshwater transfer in the gills of the euryhaline killifish Fundulus heteroclitus. Killifish were implanted with RU486 (GR antagonist) or spironolactone (MR antagonist) at doses of 0.1-1.0 mg g(-1), and subsequently transferred from 10 per thousand brackish water to freshwater. Compared to brackish water sham fish, mRNA expression of CFTR and NKCC1 decreased in the gills of sham fish transferred to freshwater, whereas Na(+), K(+)-ATPase alpha(1a) mRNA expression and alpha protein abundance, as well as cell proliferation (detected using BrdU) increased. Spironolactone inhibited the normal increase in cell proliferation and Na(+), K(+)-ATPase expression after freshwater transfer. RU486 increased plasma cortisol levels and may have slightly inhibited Na(+), K(+)-ATPase activity, but did not change alpha(1a ) expression. RU486 had no effect on cell proliferation in the non-lamellar region of the gills, but increased proliferation in the lamellar region. Neither antagonist inhibited the suppression of CFTR or NKCC1 expression after freshwater transfer. Glucocorticoid receptor expression was reduced in all sham and antagonist treatments compared to untreated controls, but no other consistent differences were observed. The effects of spironolactone suggest that MR is important for regulating ion transport in killifish gills after freshwater transfer.
Scott
Graham R
GR
Department of Zoology, University of British Columbia, Vancouver, BC, V6T 1Z4, Canada. scott@zoology.ubc.ca
Keir
Karolyn R
KR
Schulte
Patricia M
PM
D000222:Adaptation, Physiological; D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D005618:Fresh Water; D023781:Fundulidae / Q000235:genetics / Q000502:physiology*; D015870:Gene Expression / Q000187:drug effects; D005880:Gills / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D017136:Ion Transport / Q000187:drug effects; D015735:Mifepristone / Q000494:pharmacology; D000451:Mineralocorticoid Receptor Antagonists; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D011965:Receptors, Glucocorticoid / Q000037:antagonists & inhibitors / Q000502:physiology; D018161:Receptors, Mineralocorticoid / Q000502:physiology; D012623:Seawater; D028021:Sodium-Potassium-Chloride Symporters / Q000235:genetics; D000254:Sodium-Potassium-Exchanging ATPase / Q000235:genetics / Q000378:metabolism; D064506:Solute Carrier Family 12, Member 2; D013148:Spironolactone / Q000494:pharmacology
D000451:Mineralocorticoid Receptor Antagonists; D012333:RNA, Messenger; D011965:Receptors, Glucocorticoid; D018161:Receptors, Mineralocorticoid; D028021:Sodium-Potassium-Chloride Symporters; D064506:Solute Carrier Family 12, Member 2; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D013148:Spironolactone; D015735:Mifepristone; D000254:Sodium-Potassium-Exchanging ATPase